GLP-1s and PCOS: what the trials show, and how they compare with metformin
Reviewed 20 sourcesPublished by PepVault
GLP-1s for PCOS: weight, periods, testosterone and pregnancy rates in the randomized trials, against metformin, plus what the labels say about pregnancy.

- Last reviewed
- Sources
- 20
- Questions
- 7
- Compounds
- 5
The short answer
No GLP-1 is approved for PCOS, but randomized trials show real effects. In women with PCOS and excess weight, liraglutide, exenatide or semaglutide took off about 2 to 5 kg more than placebo or metformin over 3 to 6 months, and androgen levels fell. In two Chinese trials against metformin, natural pregnancy rates in the months after a 12- to 16-week course were about double.
- Weight: about 2 to 5 kg more lost than on placebo or metformin over 3 to 6 months in the PCOS trials.
- Periods and androgens improve modestly; excess hair barely moves in trials this short.
- Wegovy's label says stop at least 2 months before a planned pregnancy; tirzepatide's labels ask pill users to switch to a non-oral method or add a barrier method for 4 weeks after each start or dose increase.
- No GLP-1 is FDA-approved for PCOS as of November 2026; the first tirzepatide PCOS trial expects to finish its main measurements at the end of 2028.
Evidence: Small randomized trials (28 to 176 women, 12 to 32 weeks) of liraglutide, exenatide and semaglutide in PCOS, several open-label and most from single centres; meta-analyses of those trials rate the certainty low to moderate; FDA labels for the pregnancy and contraception guidance. No GLP-1 is FDA-approved for PCOS, and no tirzepatide or retatrutide PCOS trial has reported.

Why would a GLP-1 help PCOS at all?
PCOS (polycystic ovary syndrome) is diagnosed when two of three things are present: irregular cycles with ovulation that comes rarely or not at all, signs of high androgens (male-type hormones such as testosterone), and an ovary crowded with small follicles or a high AMH level on a blood test20. In 2026 an international consensus backed by 56 organisations renamed it polyendocrine metabolic ovarian syndrome (PMOS), because the "cysts" are arrested follicles and the condition is as much about metabolism as the ovary; the diagnostic criteria did not change20.
The metabolic side is the link. The international PCOS guideline names insulin resistance as a driver of the condition13: when cells answer insulin poorly, the body makes more of it, and a 2026 evidence review counts that excess insulin, with visceral fat and low-grade inflammation, among the forces that drive PCOS in many women17. A GLP-1 drug copies a gut hormone that slows the stomach, quiets appetite and helps insulin work, so weight and insulin both fall. The open question the trials ask is how much of the ovary follows.
PepVault's weight log charts the scale week by week, and a body check-in records your waist, two of the measures every PCOS trial here followed. Track your weight in PepVault

How much weight do women with PCOS lose on a GLP-1?
Fewer women have been studied than in the big obesity trials, and the doses were mostly older drugs at diabetes strength. These are the randomized trials that measured it, each in women with PCOS and overweight or obesity:
| Trial | Women | Drug and comparison | Length | Weight result | More than the comparison |
|---|---|---|---|---|---|
| Nylander 2017, Denmark1 | 72 | Liraglutide 1.8 mg daily vs placebo | 26 weeks | Not reported | 5.2 kg |
| Elkind-Hirsch 2022, US2 | 82 | Liraglutide 3 mg daily vs placebo, both with lifestyle help | 32 weeks | −5.7% vs −1.4% of body weight | 4.3 points of body weight |
| Liu 2017, China3 | 176 | Exenatide 10 mcg twice daily vs metformin 1,000 mg twice daily | 12 weeks | −4.3 kg vs −2.3 kg | 2.0 kg |
| Chen 2025, China6 | 100 | Semaglutide 1 mg weekly plus metformin vs metformin alone | 16 weeks | −6.1 kg vs −2.3 kg | 3.8 kg |
The pooled reviews agree on the direction and differ on the size. A Swedish health-technology review of 11 randomized trials found that a GLP-1 added to other care lowered BMI by 1.38 points more than the comparison, and rated the certainty low8. A 2026 meta-analysis of seven liraglutide trials in 330 women found lower BMI and better insulin resistance than the comparisons9. Semaglutide data in PCOS are still sparse, and no tirzepatide trial in PCOS has reported17.
Is a GLP-1 better than metformin for PCOS?
For weight, usually yes, by a few kilograms; for blood sugar, about the same. In the head-to-head trials above, exenatide took off roughly 2 kg more than metformin in 12 weeks3, and semaglutide added to metformin took off about 4 kg more than metformin alone in 16 weeks6. The meta-analysis that informed the 2023 international guideline pooled the exenatide-versus-metformin trials and found no difference in weight, androgens or insulin measures, with fasting glucose a little lower on metformin7. So the evidence is mixed across trials, and the gap was widest in the one trial of the stronger drug, semaglutide.
The guideline itself treats the two differently. It prefers metformin over the contraceptive pill for the metabolic side of PCOS, and says GLP-1 drugs such as liraglutide and semaglutide could be considered alongside lifestyle care for higher weight in adults with PCOS, as in anyone else with obesity13. Metformin is not FDA-approved for PCOS either; both are used off-label17. Many women take both; the semaglutide trial above tested that pair6.
Do periods become regular and testosterone come down?
In the best placebo trials, yes, modestly. In the Danish liraglutide trial, the share of expected bleeds that actually came (the bleeding ratio) rose by 0.28 on the drug and 0.14 on placebo; on liraglutide, SHBG (the protein that binds testosterone and keeps it inactive) rose by 7.4 nmol/L and free testosterone fell1. In the US trial of liraglutide 3 mg, the free androgen index (testosterone measured against SHBG, a single number for active androgen) fell on the drug and rose slightly on placebo2.
Pooled, the liraglutide meta-analysis found more frequent periods, a lower free androgen index and lower LH (a pituitary hormone that runs high in PCOS)9. The Swedish review was stricter and judged the evidence on menstrual regularity and excess hair too thin to call8. An Oxford review of 29 randomized comparisons in 1,529 women found that weight loss by any route, diet or drug, improved insulin resistance, the free androgen index and menstrual frequency, with no clear change in hair growth, which the authors say the data may have been too small to show12. The weight loss itself seems to carry much of the effect.
Commonly reported: periods returning or arriving more predictably within a few months, fewer sugar cravings, and nausea in the step-up weeks; excess hair is the slowest thing to change, if it changes at all.
PepVault keeps a daily note beside each dose, so the day a period starts can sit in the same record as the drug and the scale. Log it in PepVault
Do GLP-1s raise the chance of getting pregnant with PCOS?
Natural pregnancies, in the small trials so far, yes. In each trial the GLP-1 ran for 12 to 16 weeks and was then stopped before women tried to conceive, usually by switching to metformin. Three papers report it, but they come from two trials:
| Trial | Women | Natural pregnancy after the course | GLP-1 group | Metformin group |
|---|---|---|---|---|
| Guangzhou exenatide trial: Liu 20173, with its follow-up paper Li 20224 | 176 (160 in the 2022 paper) | Weeks 12 to 24 | 43.6% (29.2% in the 2022 paper) | 18.7% (14.7% in the 2022 paper) |
| Chongqing semaglutide trial: Chen 20256 | 100 (80 finished) | Weeks 16 to 40 | 35% | 15% |
The two Guangzhou papers come from the same hospital and team with the same design (exenatide 10 mcg twice daily or metformin for 12 weeks, then metformin for everyone), and the 2022 paper calls itself the long-term follow-up of a randomized trial; we count them as one trial. They give different rates for the same weeks, and neither paper explains the gap, so read the range, not either figure.
The longer view is quieter. In the Guangzhou follow-up, once IVF and other fertility treatment were added up to week 64, total pregnancy rates were 79.2% and 76%, no real difference4. A 2026 meta-analysis of three trials in 252 women found the odds of a natural pregnancy about three times higher on GLP-1-based treatment (odds ratio 3.10) but no clear gain in overall or IVF pregnancy, and asked for trials that count live births10; an earlier pooling of 11 trials in 840 women reached the same split, though it counted the two Guangzhou papers as separate trials11. A Slovenian pilot of 28 women given liraglutide 1.2 mg with metformin before IVF reported 85.7% pregnancies per embryo transfer against 28.6% on metformin alone5. The guideline's line for now: anti-obesity drugs for fertility belong in research settings13, and letrozole remains its first-line drug for ovulation13.
What do the labels say about pregnancy and the pill?
This matters in PCOS because ovulation can return as the weight comes off, sometimes before a woman expects it. The labels are plain about it:
- Wegovy (semaglutide): "discontinue WEGOVY in patients at least 2 months before they plan to become pregnant to account for the long half-life of semaglutide," and stop it when a pregnancy is recognized; its label found no meaningful change in the hormones of a combined pill14.
- Zepbound and Mounjaro (tirzepatide): Zepbound, the weight label, says to stop when a pregnancy is recognized; Mounjaro, the diabetes label, says to use it in pregnancy only if the benefit justifies the risk1516. Tirzepatide slows the stomach most after the first dose, so the labels advise anyone on a contraceptive pill to switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after starting and for 4 weeks after each dose increase; hormonal methods not taken by mouth, such as the patch, ring, implant or hormonal IUD, should not be affected1516.
- The size of that effect: after one 5 mg dose of tirzepatide, peak levels of a combined pill's hormones fell 55 to 66% and total exposure 20 to 23%15.
- The PCOS guideline: use effective contraception while on any GLP-1 when pregnancy is possible, because pregnancy safety data are lacking13.
In the fertility trials above, this is exactly how it was done: the drug came first, then a stop, then trying3456. Planning a pregnancy on a GLP-1 means planning the stop date with the prescriber; which drug, if any, and for how long is the prescriber's decision.
When to get help A positive pregnancy test while taking a GLP-1 is a reason to call your prescriber that week, since the Wegovy and Zepbound labels say to stop once a pregnancy is known1415.
PepVault's reminders follow your dose schedule, and the dose log shows the date of your last shot, the date a stop plan counts from. Set reminders in PepVault
Is any GLP-1 approved for PCOS, and what is coming?
As of November 2026, no. The current Wegovy, Zepbound and Mounjaro labels list obesity, diabetes, heart risk, sleep apnea and MASH among their uses, and none names PCOS141516. A woman with PCOS can be prescribed one for weight under the usual obesity criteria, which is the use the guideline backs13.
- Tirzepatide: no PCOS trial has reported, and a 2026 evidence map says it cannot be recommended for PCOS beyond what the obesity trials show17. The first trial is running at the University of Bonn: 198 women aged 18 to 45, tirzepatide or placebo for 72 weeks, with menstrual regularity as the main measure and ovulation next; estimated primary completion December 202818.
- Semaglutide: the University of Colorado is testing whether 10 months of semaglutide restores ovulation in 80 girls and women aged 12 to 35, without a placebo group; estimated primary completion February 202819.
- Retatrutide: no PCOS trial is registered at ClinicalTrials.gov as of November 20, 2026.
Sources
- Nylander M, Frøssing S, Clausen HV, Kistorp C, Faber J, Skouby SO. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reprod Biomed Online. 2017;35(1):121-127. PubMed 28479118
- Elkind-Hirsch KE, Chappell N, Shaler D, Storment J, Bellanger D. Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled phase 3 study. Fertil Steril. 2022;118(2):371-381. PubMed 35710599
- Liu X, Zhang Y, Zheng SY, et al. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome. Clin Endocrinol (Oxf). 2017;87(6):767-774. PubMed 28834553
- Li R, Mai T, Zheng S, Zhang Y. Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT. Arch Gynecol Obstet. 2022;306(5):1711-1721. PubMed 35829765
- Salamun V, Jensterle M, Janez A, Vrtacnik Bokal E. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur J Endocrinol. 2018;179(1):1-11. PubMed 29703793
- Chen H, Lei X, Yang Z, et al. Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial. Reprod Biol Endocrinol. 2025;23(1):108. PubMed 40713699
- Goldberg A, Graca S, Liu J, et al. Anti-obesity pharmacological agents for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 international evidence-based guideline. Obes Rev. 2024;25(5):e13704. PubMed 38355887
- Forslund M, Wändell P, Forsberg L, et al. GLP-1 receptor agonist treatment in women with polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Endocrinol. 2026;194(3):25-39. PubMed 41701618
- Lu YT, Chang PH, Chen HJ, et al. Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: a systematic review and meta-analysis. Diabetes Obes Metab. 2026;28(4):2523-2535. PubMed 41508932
- Kar E, Yeh J, Efe MA, et al. The effect of glucagon-like peptide-1 receptor agonists versus metformin on pregnancy rates in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized trials. Eur J Obstet Gynecol Reprod Biol. 2026;327:115499. PubMed 42893679
- Zhou L, Qu H, Yang L, Shou L. Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review. BMC Endocr Disord. 2023;23(1):245. PubMed 37940910
- Scragg J, Hobson A, Willis L, et al. Effect of weight loss interventions on the symptomatic burden and biomarkers of polycystic ovary syndrome: a systematic review of randomized controlled trials. Ann Intern Med. 2024;177(12):1664-1674. PubMed 39496172
- Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-2469 (recommendations 1.9.12, 4.4, 4.5, 5.3 and 5.9). PubMed 37580314
- Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information (DailyMed, SPL version 19, revised 06/2026): sections 1, 8.1, 8.3 and 12.3. dailymed.nlm.nih.gov
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information (DailyMed, SPL version 40, revised 08/2026): sections 1, 7.2, 8.1, 8.3 and 12.3. dailymed.nlm.nih.gov
- Eli Lilly and Company. MOUNJARO (tirzepatide) injection, prescribing information (DailyMed, SPL version 40, 08/2026): sections 1, 8.1 and 8.3. dailymed.nlm.nih.gov
- Jensterle M, Janez A. Incretin-based anti-obesity medications in polycystic ovary syndrome: the evidence map. Drugs. 2026;86(7):1013-1032. PubMed 42106472
- University of Bonn. A clinical trial of tirzepatide (LY3298176) in subjects with overweight or obesity and PCOS-related ovarian dysfunction (NCT07326111). ClinicalTrials.gov. clinicaltrials.gov
- University of Colorado, Denver. Role of semaglutide in restoring ovulation in youth and adults with polycystic ovary syndrome (NCT05819853). ClinicalTrials.gov. clinicaltrials.gov
- Bahri-Khomami M, Hoeger KM, Huddleston H, Mahalingaiah S, Teede HJ, Dokras A. From polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome: what obstetricians and gynecologists need to know. Am J Obstet Gynecol. 2026;235(5):999-1002. PubMed 42665241
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.